Inhibitory Impact of a Mesoporous Silica Nanoparticle-based Drug Delivery System on Porphyromonas Gingivalis-induced Bone Resorption

Overview

Journal J Mater Sci Mater Med

Publisher Springer

Specialty Biomedical Engineering

Date 2024 Sep 30

PMID 39347836

Authors

Mengya Li

Jian Sun

Dong Zhao

Wen Zhang

Qingan Xu

Affiliations

Soon will be listed here.

Abstract

Controlling and reducing plaque formation plays a pivotal role in preventing and treating periodontal disease, often utilizing antibacterial drugs to enhance therapeutic outcomes. Mesoporous silica nanoparticles (MSN), an FDA-approved inorganic nanomaterial, possess robust physical and chemical properties, such as adjustable pore size and pore capacity, easy surface modification, and high biosafety. Numerous studies have exploited MSN to regulate drug release and facilitate targeted delivery. This study aimed to synthesize an MSN-tetracycline (MSN-TC) complex and investigate its inhibitory potential on Porphyromonas gingivalis (P. gingivalis)-induced bone resorption. The antibacterial efficacy of MSN-TC was evaluated through bacterial culture experiments. A P. gingivalis-induced bone resorption model was constructed by subcutaneously injecting P. gingivalis around the cranial bone of rats. Micro-computed tomography was employed to assess the inhibitory impact of MSN and MSN-TC on bone resorption. Furthermore, the influence of MSN and MSN-TC on osteoclast differentiation was examined in vitro. The MSN exhibited optimal pore size and particle dimensions for effective loading and gradual release of TC. MSN-TC demonstrated significant bacteriostatic activity against P. gingivalis. MSN-TC-treated rats showed significantly reduced cranial bone tissue destruction compared to MSN or TC-treated rats. Additionally, both MSN and MSN-TC exhibited inhibitory effects on the receptor activator of nuclear factor kappa-Β ligand-mediated osteoclast differentiation. The MSN-TC complex synthesized in this study demonstrated dual efficacy by exerting antibacterial effects on P. gingivalis and by resisting osteoclast differentiation, thereby mitigating bone resorption induced by P. gingivalis.

References

Kinane D, Stathopoulou P, Papapanou P . Periodontal diseases. Nat Rev Dis Primers. 2017; 3:17038. DOI: 10.1038/nrdp.2017.38. View

Slots J . Periodontitis: facts, fallacies and the future. Periodontol 2000. 2017; 75(1):7-23. DOI: 10.1111/prd.12221. View

Pihlstrom B, Michalowicz B, Johnson N . Periodontal diseases. Lancet. 2005; 366(9499):1809-20. DOI: 10.1016/S0140-6736(05)67728-8. View

Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S . A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodontol. 2003; 29 Suppl 3:136-59; discussion 160-2. DOI: 10.1034/j.1600-051x.29.s3.8.x. View

Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T . Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020; 47 Suppl 22:4-60. PMC: 7891343. DOI: 10.1111/jcpe.13290. View

Chopra I, Roberts M . Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65(2):232-60 ; second page, table of contents. PMC: 99026. DOI: 10.1128/MMBR.65.2.232-260.2001. View

Addy M, Martin M . Systemic antimicrobials in the treatment of chronic periodontal diseases: a dilemma. Oral Dis. 2003; 9 Suppl 1:38-44. DOI: 10.1034/j.1601-0825.9.s1.7.x. View

Miller C, McGarity G . Tetracycline-induced renal failure after dental treatment. J Am Dent Assoc. 2009; 140(1):56-60. DOI: 10.14219/jada.archive.2009.0018. View

Wright J, Paauw D . Complications of antibiotic therapy. Med Clin North Am. 2013; 97(4):667-79, xi. DOI: 10.1016/j.mcna.2013.02.006. View

10.

Jones D, Woolfson A, Brown A, Coulter W, McClelland C, Irwin C . Design, characterisation and preliminary clinical evaluation of a novel mucoadhesive topical formulation containing tetracycline for the treatment of periodontal disease. J Control Release. 2000; 67(2-3):357-68. DOI: 10.1016/s0168-3659(00)00231-5. View

11.

Sindhura Reddy N, Sowmya S, Bumgardner J, Chennazhi K, Biswas R, Jayakumar R . Tetracycline nanoparticles loaded calcium sulfate composite beads for periodontal management. Biochim Biophys Acta. 2014; 1840(6):2080-90. DOI: 10.1016/j.bbagen.2014.02.007. View

12.

Chen L, Zhou X, He C . Mesoporous silica nanoparticles for tissue-engineering applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11(6):e1573. DOI: 10.1002/wnan.1573. View

13.

Thomas M, Slipper I, Walunj A, Jain A, Favretto M, Kallinteri P . Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. Int J Pharm. 2009; 387(1-2):272-7. DOI: 10.1016/j.ijpharm.2009.12.023. View

14.

Zhang Y, Wang J, Bai X, Jiang T, Zhang Q, Wang S . Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol Pharm. 2012; 9(3):505-13. DOI: 10.1021/mp200287c. View

15.

Biswas N . Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan. Eur J Pharm Sci. 2016; 99:152-160. DOI: 10.1016/j.ejps.2016.12.015. View

16.

Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y . Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC). Biomed Pharmacother. 2020; 125:109561. DOI: 10.1016/j.biopha.2019.109561. View

17.

Juneja R, Vadarevu H, Halman J, Tarannum M, Rackley L, Dobbs J . Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro. ACS Appl Mater Interfaces. 2020; 12(35):38873-38886. PMC: 7748385. DOI: 10.1021/acsami.0c07106. View

18.

Yang J, Dai D, Lou X, Ma L, Wang B, Yang Y . Supramolecular nanomaterials based on hollow mesoporous drug carriers and macrocycle-capped CuS nanogates for synergistic chemo-photothermal therapy. Theranostics. 2020; 10(2):615-629. PMC: 6929989. DOI: 10.7150/thno.40066. View

19.

Zhou Y, Quan G, Wu Q, Zhang X, Niu B, Wu B . Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B. 2018; 8(2):165-177. PMC: 5926503. DOI: 10.1016/j.apsb.2018.01.007. View

20.

Li Z, Zhang Y, Feng N . Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery. Expert Opin Drug Deliv. 2019; 16(3):219-237. DOI: 10.1080/17425247.2019.1575806. View